KR20250117836A - 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 - Google Patents
자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법Info
- Publication number
- KR20250117836A KR20250117836A KR1020257024754A KR20257024754A KR20250117836A KR 20250117836 A KR20250117836 A KR 20250117836A KR 1020257024754 A KR1020257024754 A KR 1020257024754A KR 20257024754 A KR20257024754 A KR 20257024754A KR 20250117836 A KR20250117836 A KR 20250117836A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- patient
- administered
- dose
- amh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515268P | 2017-06-05 | 2017-06-05 | |
| US62/515,268 | 2017-06-05 | ||
| PCT/EP2018/064768 WO2018224498A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| KR1020197038977A KR102839190B1 (ko) | 2017-06-05 | 2018-06-05 | 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197038977A Division KR102839190B1 (ko) | 2017-06-05 | 2018-06-05 | 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250117836A true KR20250117836A (ko) | 2025-08-05 |
Family
ID=62620835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257024754A Pending KR20250117836A (ko) | 2017-06-05 | 2018-06-05 | 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 |
| KR1020197038977A Active KR102839190B1 (ko) | 2017-06-05 | 2018-06-05 | 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197038977A Active KR102839190B1 (ko) | 2017-06-05 | 2018-06-05 | 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11980621B2 (https=) |
| EP (1) | EP3634418A1 (https=) |
| JP (2) | JP7348171B2 (https=) |
| KR (2) | KR20250117836A (https=) |
| CN (1) | CN110996956A (https=) |
| AU (2) | AU2018280742B2 (https=) |
| CA (1) | CA3066190A1 (https=) |
| EA (1) | EA201992612A1 (https=) |
| MA (1) | MA49256A (https=) |
| MX (1) | MX2019014483A (https=) |
| SG (1) | SG11201911598WA (https=) |
| WO (1) | WO2018224498A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| KR102884301B1 (ko) | 2017-06-05 | 2025-11-11 | 깃세이 야쿠힌 고교 가부시키가이샤 | 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 |
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| CA3117092A1 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| CN114466665A (zh) * | 2019-08-08 | 2022-05-10 | 奥布赛瓦股份公司 | 用于治疗雌激素依赖性病症的组合物和方法 |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| WO2022101303A1 (en) * | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| CN116940575A (zh) * | 2021-02-23 | 2023-10-24 | 深圳市康哲药业有限公司 | 噻吩并嘧啶二酮类化合物及其应用 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342760A (en) | 1992-06-10 | 1994-08-30 | Abbott Laboratories | Determination of estradiol by competitive immunoassay |
| US5663054A (en) | 1995-03-03 | 1997-09-02 | Abbott Laboratories | Determination of steroids by competitive immunoassay |
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| CN1186326C (zh) | 2000-07-05 | 2005-01-26 | 山之内制药株式会社 | 丙－1,3－二酮衍生物 |
| US7300935B2 (en) | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
| CN100424078C (zh) | 2003-07-07 | 2008-10-08 | 纽罗克里生物科学有限公司 | 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物 |
| SI1864976T1 (sl) | 2005-03-31 | 2012-12-31 | Astellas Pharma Inc. | Propan-1,3-dionski derivat ali njegova sol |
| KR101384132B1 (ko) | 2005-10-19 | 2014-04-10 | 깃세이 야쿠힌 고교 가부시키가이샤 | 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도 |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| SG183243A1 (en) | 2010-02-10 | 2012-09-27 | Kissei Pharmaceutical | Salt of fused heterocyclic derivative and crystal thereof |
| AP2014007738A0 (en) | 2012-01-16 | 2014-07-31 | Bayer Ip Gmbh | Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists |
| US20130224771A1 (en) | 2012-02-21 | 2013-08-29 | Northwestern University | Anti-mullerian hormone detection in whole blood |
| KR20150048762A (ko) | 2012-09-07 | 2015-05-07 | 아스텔라스세이야쿠 가부시키가이샤 | 술포닐아미딘 화합물의 제조법 |
| WO2014042176A1 (ja) | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| AR092707A1 (es) | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| US10881659B2 (en) | 2013-03-15 | 2021-01-05 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| AR095785A1 (es) | 2013-04-09 | 2015-11-11 | Bayer Pharma AG | Derivados de espiroindolina y composiciones farmacéutica de los mismos |
| AU2016317955B2 (en) | 2015-09-01 | 2021-05-20 | Abbvie Inc. | Methods of administering Elagolix |
| TWI746613B (zh) * | 2016-08-08 | 2021-11-21 | 日商橘生藥品工業股份有限公司 | 子宮內膜病症治療劑之用法及用量 |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| KR102884301B1 (ko) | 2017-06-05 | 2025-11-11 | 깃세이 야쿠힌 고교 가부시키가이샤 | 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 |
| SG11202104053TA (en) | 2018-11-07 | 2021-05-28 | ObsEva SA | Compositions and methods for the treatment of estrogen-dependent disorders |
-
2018
- 2018-06-05 EA EA201992612A patent/EA201992612A1/ru unknown
- 2018-06-05 EP EP18731378.8A patent/EP3634418A1/en active Pending
- 2018-06-05 MX MX2019014483A patent/MX2019014483A/es unknown
- 2018-06-05 KR KR1020257024754A patent/KR20250117836A/ko active Pending
- 2018-06-05 WO PCT/EP2018/064768 patent/WO2018224498A1/en not_active Ceased
- 2018-06-05 CN CN201880050650.3A patent/CN110996956A/zh active Pending
- 2018-06-05 MA MA049256A patent/MA49256A/fr unknown
- 2018-06-05 US US16/619,776 patent/US11980621B2/en active Active
- 2018-06-05 AU AU2018280742A patent/AU2018280742B2/en active Active
- 2018-06-05 JP JP2020516959A patent/JP7348171B2/ja active Active
- 2018-06-05 KR KR1020197038977A patent/KR102839190B1/ko active Active
- 2018-06-05 CA CA3066190A patent/CA3066190A1/en active Pending
- 2018-06-05 SG SG11201911598WA patent/SG11201911598WA/en unknown
-
2023
- 2023-05-23 JP JP2023084336A patent/JP7657855B2/ja active Active
-
2024
- 2024-03-14 AU AU2024201701A patent/AU2024201701B2/en active Active
- 2024-04-12 US US18/634,241 patent/US20240293414A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018224498A1 (en) | 2018-12-13 |
| JP2020522571A (ja) | 2020-07-30 |
| CN110996956A (zh) | 2020-04-10 |
| AU2024201701A1 (en) | 2024-04-04 |
| US20200138819A1 (en) | 2020-05-07 |
| AU2018280742B2 (en) | 2023-12-21 |
| JP7348171B2 (ja) | 2023-09-20 |
| US11980621B2 (en) | 2024-05-14 |
| KR102839190B1 (ko) | 2025-07-28 |
| CA3066190A1 (en) | 2018-12-13 |
| JP7657855B2 (ja) | 2025-04-07 |
| SG11201911598WA (en) | 2020-01-30 |
| AU2018280742A1 (en) | 2020-01-30 |
| AU2024201701B2 (en) | 2025-04-10 |
| JP2023113715A (ja) | 2023-08-16 |
| KR20200027481A (ko) | 2020-03-12 |
| EA201992612A1 (ru) | 2020-05-20 |
| MA49256A (fr) | 2021-05-26 |
| US20240293414A1 (en) | 2024-09-05 |
| EP3634418A1 (en) | 2020-04-15 |
| MX2019014483A (es) | 2020-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7657855B2 (ja) | 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 | |
| JP7485815B2 (ja) | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 | |
| US20230067378A1 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| US20220288154A1 (en) | Gnrh antagonists for the treatment of estrogen-dependent disorders | |
| US20220305017A1 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| US12280052B2 (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis | |
| EA044130B1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза | |
| EA049129B1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери | |
| HK40027583A (en) | Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |